Company intelligence / Profile preview

AESIS Therapeutics

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

AESIS Therapeutics is a clinical-stage biotechnology company based in South Korea that specializes in developing innovative treatments for hearing loss. The company's primary focus is on sensorineural hearing loss, a condition often caused by the damage or loss of hair cells in the inner ear. Their lead candidate, AIS-101, is a small molecule designed to promote the regeneration of these hair cells by modulating the Notch signaling pathway. AESIS Therapeutics aims to address significant unmet medical needs in the otology space through regenerative medicine approaches.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on AESIS Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AESIS Therapeutics.

Explore the full profile